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Infectious bursal disease (IBD) is a viral disease of young chickens that produce severe lesions in the bursa of
Fabricius and other organs inducing immunosuppression and mortality in birds. This study indicates that oral
administration of IFN-α and IL-2 during 16 days produced a significant reduction in animals’ morbidity and mortality
to IBD virus (IBDV) infection accompanied with a decrease in symptoms and bursal tissue damage. The treatment
also increased body weight, not only in birds challenged with IBDV, but also in uninfected controls. Infected birds
treated with cytokines presented the same bursal index and organs’ weight that controls; since untreated animals
showed a significant decrease in these parameters. Finally, cytokine administration represents a new alternative to
IBDV vaccination.
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Introduction
Infectious bursal disease (IBD) is a viral immunosuppres-
sive disease of young chickens attacking mainly the bursa of
Fabricius, an important lymphoid organ in newly born birds.
Emergence of new variant strains of the causative agent, the
infectious bursal disease virus (IBDV), has made it more
urgent to develop new treatment strategies against IBD. Use
of recombinant vaccines is one of these strategies, but al-
ternative preventive approaches are also a priority.
IBD is an acute, highly contagious and immunosuppres-
sive disease of young chickens (Sharma et al., 2000). The
causative agent, IBDV, belongs to family Birnaviridae. The
virus infects and destroys actively dividing IgM-bearing B
cells in the bursa of Fabricius (Hirai et al., 1981; Rodenberg
et al., 1994). Replication of IBDV in the bursa is accom-
panied by an influx of T cells (Tanimura and Sharma, 1997;
Kim et al., 1999, 2000; Sharma et al., 2000). Although the
bursal T cells are activated and proliferate in vitro, when
stimulated by purified IBDV, there is strong evidence that T
cells do not serve as targets for infection and replication of
IBDV (Kim et al., 2000). However, there are reports that
macrophages and monocytes may be susceptible to infection
with the virus (Käufer and Weiss, 1976, 1980; Burkhardt
and Müller, 1987; Komine et al., 1989; Inoue et al., 1992;
Lam, 1998; Khatri et al., 2005; Palmquist et al., 2006).
Most commercially available conventional live IBDV vac-
cines are based on classical virulent strains. Those classified
as “mild” vaccines exhibit only poor efficacy in the presence
of certain levels of maternally derived antibodies and against
very virulent IBDV. “Intermediate” and “intermediate plus”
or “hot” vaccines have a much better efficacy and may break
through higher levels of maternally derived antibodies, but
they can induce moderate to severe bursal lesions, and thus,
cause corresponding levels of immunosuppression
(Mazariegos et al., 1990; Tsukamoto et al., 1995; Kumar et
al., 2000). These vaccines may not fully protect chickens
against infection by the very virulent IBDV strains
(Rautenschlein et al., 2005) or by antigenic variants. Safety
and efficacy of such vaccines still remain a major concern.
In addition, the practical on farm administration of the
conventional live vaccines to a large number of animals is
also a technically demanding process, with difficulties in-
herent to farm-to-farm variability (variable chicks, variable
farming conditions, variable skills in vaccination crews, etc.)
that should not be underestimated, when assessing the results
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of vaccination programs. Non-replicating antigens, such as
inactivated whole viruses, viral subunits or recombinant viral
antigens, are not immunogenic enough unless they are
combined with supporting adjuvants and administered in
repeated injections, or follow suitable priming with a
replicating antigen. Need for possible repeat injection ob-
viously contributes to the implementation costs of these
vaccines, and their use is usually restricted to highly valuable
birds, such as future breeder birds, vaccination before lay
provides passive immunity to the offspring by means of
maternally derived antibodies. However, such vaccines have
also been used occasionally in birds as young as 10 days old,
particularly in areas heavily contaminated with virulent
viruses (Wyeth and Chettle, 1990). Inactivated IBDV vac-
cines are mostly formulated as water-in-oil emulsions,
usually combining several antigens. It has been observed
that inactivated IBDV vaccines were also able to induce
IBDV-specific T-cell and inflammatory responses in
chickens (Rautenschlein et al., 2002). It has been reported
that inactivated IBDV vaccines must have either a high or an
optimized antigenic content to induce an immunity in
breeders that helps protect the progeny from infection by
variant IBDV strains (Rosenberger and Cloud, 1989; Müller
et al., 1992). Inactivated vaccines are most efficiently used
in a prime-boost regimen, using attenuated live IBDV as
priming vaccine.
Cytokines are key communication molecules between host
cells in the defense against pathogens. Bacterial and viral
infections induce expression of multiple chemokines and
proinflammatory cytokines. In this work, use of cytokines
was evaluated as IBDV preventive treatment.
Materials and Methods
Reagents— Recombinant avian interferon α (IFN-α) and
interleukin 2 (IL-2) were purchased from Alquimia Labo-
ratory (Buenos Aires, Argentina).
Animals— White Cornish chicks were obtained from
“Avicola Areco” poultry farm in Buenos Aires, Argentina.
Eggs without vaccination from Gumboro-free egg-laying
hens were randomly selected from the incubation plant. Two
hundred 5-days old chicks were individualized by number-
ing, randomly separated in four groups and grown in distinct
battery cages, fed with non-sterile pellets (coccidia-free) and
water ad libitum. All animals were tested for maternally
derived antibodies against IBDV.
Animal Treatments and Data Collection— White Cornish
chicks were randomly divided into four identical groups (N
＝50): control group 1 without treatment, group 2 treated
with cytokines, group 3 challenged with IBDV, and group 4
treated with cytokines and challenged with IBDV. Cyto-
kines viz., recombinant avian IFN-α and IL-2, were ad-
ministered to groups 2 and 4 ad libitum mixed in the drinking
water for 16 days. Three days after the first dose groups 3
and 4 were infected using an intraocular administration of the
IBDV. Fig. 1A shows a timeline scheme of the mentioned
experimental protocol. Animals were challenged using a
standard IBDV, sample standard virulent type virus from the
serotype 1 (Remorini et al., 2006). IBDV was maintained in
specific pathogens free embryonated eggs. At day 8, chicks
were infected with IBDV (10
4
infective doses per 50ml) by a
non-invasive intraocular inoculation technique. Cytokines
were administrated, from day 5, diluted in water at a final
concentration of 1,000U/ml of recombinant avian IFN-α and
IL-2. The cytokines solution was administered ad libitum in
poultry drinkers as the sole source of liquid available. The
consumption of this solution was not significantly different
from regular water consumption on the poultry farm. Chick
body weight was determined every 5 days by two inde-
pendent operators.
Histopathological Analysis— The chicks were euthanized
by cervical dislocation. Internal organ weight, tissue sample
preparation and microscopic analysis were performed. Bursa
were collected, fixed in 10% formalin, dehydrated in a series
of alcohol concentrations, embedded in paraffin wax, sec-
tioned at 5 μm thickness and stained with haemotoxylin and
eosin.
Scoring of Clinical Manifestations— The infected birds
were euthanized and analyzed at day 25
th
. Bursae’ histo-
pathological grades and numerical scores (I-III) were adapted
from previous works (Johnson and Reid, 1970; Mattiello et
al., 2000) and defined according to the folds or plicae (F),
pseudostratified columnar epithelium (PCE), lymphoid
follicles (LF), and interfollicular areas (IA), as described
below:
Grade I (normal): F, large, spike shape, plenty; PCE,
straight, without goblet cell or cyst; LF, large, uniform,
tightly packed; IA, scanty.
Grade II (moderate): F, short, non-uniform, separate; PCE,
wavy invaginated, few goblet cell, cyst formations; LF,
small, irregular, pallor reticular center; IA, wide with oe-
dema.
Grade III (severe): F, small, deformed, scanty; PCE, ir-
regular invaginated, plenty goblet cells, cyst formation; LF,
small or absent, very irregular, cyst formations; IA, stromal
fibroplasia.
Dead animals between the day 5 and 25 were classified as
grade IV.
Statistics— Proportions of diseased animals were compared
between groups using the Chi-square test and post-hoc
comparisons. Distribution of scoring data was analyzed
using Kolmogorov-Smirnov test followed by a Kruskal-
Wallis non-parametric comparison. Analyses were per-
formed using the SPSS Statistics software version 11.5
(IBM).
Results and Discussion
Effect of Cytokines on the Poultry Weight. Initial pool of
chicks (5-days old) showed no significant differences in the
body weight according to Kolmogorov-Smirnov test (p＝
0.001). After 25 days, the population did not present a
normal distribution, so; all the statistical analyses were
performed using non-parametric tests. On day 25, the popu-
lation presented a significant weight differences according to
a Kruskal-Wallis test (p＝0.009). Post hoc analyses (Mann-
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Whitney) showed significant differences between IBDV
infected treated and untreated chicks (p＝0.03) and also the
controls treated and untreated (p＝0.037). These results
demonstrated that administration of cytokines produced an
increase in the body weight of about 11-12% not only on
infected chicks, but also on normal animals (Fig. 1B).
Increase in body weight of treated uninfected birds could be
due to a protective effect of cytokines on other pathogens and
protection of the intestinal flora thus improving the weight
performance and feed conversion (Torok et al., 2011).
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Fig. 1. A) Experimental protocol scheme. 200 White Cornish 5-days
old chicks were divided into 4 groups. Cytokines were administrated
from day 5 to day 20 to chicks from groups 2 and 4. At day 8, chicks
from groups 3 and 4 were infected with IBDV. Chick body weight
was determined each 5 days. B) Weight measures. Body weights from
all the chicks were determined from day 5 to day 25 (large set).
Weight differences over the control group 1 were calculated for day
25 (inset).
However, further investigation on this topic is required.
Detailed weight differences over the control chicks (group 1)
were 85.7 g, −49.7 g and 39.2 g of the groups 2, 3 and 4,
respectively (inset Fig. 1B).
Animals’ Morbidity and Mortality. On the other hand, death
rates over 50 chicks per group were 3, 0, 6 and 1 (chi-
square: X (3)＝8.84, p＝0.031) and the animals with IBDV
symptoms were 0, 0, 21 and 14 (chi-square: X (3)＝45.818,
p＝0.0001) for groups 1, 2, 3 and 4, respectively. The
results demonstrated a significant difference in mortality and
morbidity on animals treated with cytokines (Fig. 2A).
Finally, different organs were analyzed post-mortem. The
bursa weight/body weight ratio (bursal index) showed that
only group 3 is below the cut-off value of 1.8 (Fig. 2B).
One-factor ANOVA and post hoc comparisons (DMS),
showed statistically significant differences between IBDV
infected treated and untreated chicks on the weight of the
bursa (p＝0.01) and thymus (p＝0.01), but not on spleen (p
＝0.36) and liver (p＝0.19) (Fig. 2C). All bar graphics in
Fig. 2 include the standard deviation.
Histopathological Analyses. Fig. 3 shows, the cellular struc-
ture of bursae from IBDV infected and control animals were
completely different. Groups 1 (panel 1, control without
treatment) and 2 (panel 2, treated control) were classified as
grade I, presenting large and regular lymphoid follicles with
an abundant population of lymphocytes. Bursae structures of
group 1 presented follicle cortexes of moderate thickness
with a normal follicular epithelium and a medullary zone
with a regular quantity of lymphocytes. However, group 2
showed an increased follicle cortex width and a higher
follicular epithelium which could be attributed to the cyto-
kine treatment. Insets from panels 1 and 2 revealed large and
abundant folds with a spike shape in both groups. Groups 3
and 4 were infected animals without (panel 3) or with (panel
Journal of Poultry Science, 52 (2)148
Fig. 2. A) Animals morbidity and mortality. The number of dead
animals and symptomatic chicks per group were determined. B)
Bursal index. The bursa weight/body weight ratio was calculated.
C) Organ differences. Typical IBD affected organs were weighed
post mortem. Error bars mean the standard deviation.
4) cytokine treatment. As panel 3 showed, IBDV infection
produced a significant decrease in the lymphoid follicles size,
an irregular cell shape and a scarce lymphocyte population
into the cortical and medullary zone. Bursae also presented a
shorter follicular epithelium, interfollicular oedema, and
hyperplasia of pseudostratified columnar epithelium. Bursae
have scarce and small folds, and lymphoid follicles with a
reduced number of lymphocytes (panel 3, inset). These
samples were classified as grade III. Finally, comparing
with group 3, the cytokine treatment produced an increase in
the lymphocyte number into the lymphoid follicles (panel 4)
and longer folds (panel 4, inset). These bursae were
classified as grade II. In addition, goblet cells were observed
in groups 3 and 4 (“G” arrows in panel 3 and 4).
Summarizing, the results demonstrated that oral adminis-
tration of IFN-α and IL-2 to 5- days old chicks during 16
days reduced morbidity and mortality to IBDV infection,
accompanied with decrease in symptoms and tissue damage
in the bursa. We speculated that T-dependent lymphocyte
system might be stimulated by IFN-α. Therefore, these acti-
vated T-lymphocytes present IL-2 receptors, and, external
administration of recombinant IL-2 produces the stimulation
of such selected clones. In addition, it could be hypothesized
that cytokine administration generates an augmented re-
sistance to other viruses different to IBDV. For example,
oral administration of chicken IFN-α inhibits avian influenza
virus replication (Meng et al., 2011). In other economically
relevant animals, such as cattle, the same cytokines were
used in combination with inactivated bacteria improving the
bovine conjuctival immune response to the pathogen
Moraxella bovis, the causative agent of infectious bovine
keratoconjunctivitis (di Girolamo et al., 2012).
An important feature of the treatment was the increase in
body weight not only in IBDV infected animals, but also in
controls. Considering the estimated production cost of
cytokines for veterinary use, implementation of the treatment
will be economically suitable for poultry producers, this
industry worldwide, and especially in Argentina. In recent
years, very virulent strains of IBDV, causing severe mortality
in chickens, have emerged in Europe, Latin America, South-
East Asia, Africa and the Middle East (Müller et al., 2003);
therefore, the cytokine treatment could be a new alternative
to vaccination.
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